Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

A case-control study was designed with 80 participants diagnosed with Barrett's Esophagus (BE) selected from a larger case-cohort study (Li et al., 2014, PMID: 24253313) within the Seattle Barrett's Esophagus Program (SBEP) at the Fred Hutchinson Cancer Research Center. The study included 40 cases with BE with non-cancer outcomes, "NCO", who did not progress to esophageal adenocarcinoma (EA), and 40 controls who progressed to an endoscopically detected, incident EA (cancer outcome, "CO"). For each patient, two timepoints were evaluated (T1 and T2). NCO were matched to CO based on age at T1 (T1=first endoscopy with sufficient sample availability), and time between T1 and T2 (T2 in CO=time of diagnosis of incident EA). In 10 NCO, a third time point (T3), a mean of 13.2 years after T1, was also sequenced. Mapped endoscopic biopsies, at 1/3 and 2/3 annotated distances from the gastroesophageal junction within the Barrett's segment, were sampled per patient at each timepoint. Each biopsy was purified to separate BE epithelium from stroma, and DNA was extracted from purified epithelium for 60X WGS and 2.5M SNP array; normal control blood (N=62) or normal gastric sample (N=18) were analyzed by 30X WGS and 2.5M SNP array. An additional seven normal gastric biopsy samples in seven patients with normal control blood were also sequenced at 60X as controls.

All research participants contributing clinical data and esophageal samples to this study provided written informed consent, subject to oversight by the Fred Hutchinson Cancer Research Center IRB Committee D (Reg ID 5619).

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Inclusion criteria included ≥ 2 endoscopies each with ≥ 3 cm segment of BE and none of the following interventions: no endoscopic mucosal resection, radio frequency ablation, photodynamic therapy, or esophageal surgical resection. Cases ("cancer outcome") were defined as participants who progressed to diagnosis of esophageal adenocarcinoma (EA), N=40. Controls ("non-cancer outcome") were defined as those who did not progress to EA during follow-up. For each case, controls were randomly selected using matching criteria of baseline total somatic chromosomal alterations (SCA) from (Li et al., 2014, PMID: 24253313) and time between timepoints T1 and T2. T1 was defined as either the baseline (N=5) or the baseline+1 (N=75) endoscopy, depending on tissue availability. T2 was defined as endoscopy during which EA was initially diagnosed for cancer outcome patients, or the endoscopy selected for matched follow-up time for non-cancer outcome patients.

Molecular Data
TypeSourcePlatformNumber of Oligos/SNPsSNP Batch IdComment
Whole Genome Genotyping Illumina Infinium Omni2.5-8 v1.3 N/A N/A
Whole Genome Genotyping Illumina Infinium Omni2.5-8 v1.2 N/A N/A Version 8v1.2 used for only one sample 391-23521-155R-31
Study History

The Seattle Barrett's Esophagus Study (SBES), which was founded in 1983 as a prospective observational cohort study of patients with Barrett's esophagus (BE), and now comprises more than 1000 patients and includes a biorepository of biospecimens and associated clinical and epidemiologic data. BE is the only known precursor to esophageal adenocarcinoma (EA), which has an estimated annual incidence of 0.5% to 1.0%, yet BE is primarily an indolent disease that will not progress to cancer during the lifetime of most patients. However the incidence of esophageal adenocarcinoma is known to be increasing at an alarming rate in many western countries, rising nearly 600% in the US over the three decades from 1972 - 2002. The overarching goals of the SBES are to (1) reduce morbidity and mortality of EA by early detection, prevention, or both and (2) elucidate mechanisms of human neoplastic progression in vivo that may be shared by other neoplasms whose early stages are less amenable to investigation. The study has over 35 years of experience in early translational research studies as defined by the NCI Translational Research Working Group.

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
See articles in PMC citing this study accession
Study Attribution
  • Co-Principal Investigators
    • Brian J. Reid, MD, PhD. Departments of Medicine and Genome Sciences, University of Washington, Seattle, WA, and Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Xiaohong Li, PhD. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Co-Investigators
    • Thomas G. Paulson, PhD. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Patricia C. Galipeau. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Kenji M. Oman, PhD. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Carissa A. Sanchez. Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    • Mary K. Kuhner, PhD. Department of Genome Sciences, University of Washington and Brotman Baty Institute of Precision Medicine, Seattle WA, USA.
    • Lucian Smith, PhD. Department of Genome Sciences, University of Washington, Seattle, WA, USA.
    • Minita Shaw, MS. New York Genome Center, New York, NY, USA.
    • Kanika Arora. New York Genome Center, New York, NY, USA.
    • Andre Corvelo, PhD. New York Genome Center, New York, NY, USA.
    • Molly Johnson. New York Genome Center, New York, NY, USA.
    • Anne-Katrin Emde, PhD. Variant Bio, Brooklyn, New York, NY, USA.
    • Jennifer Shelton, MS. New York Genome Center, New York, NY, USA.
    • Carlo C. Maley, PhD. Arizona State University, Tempe, AZ, USA.
    • Xiaotong Yao. New York Genome Center, New York, NY, USA.
    • Kevin Hadi. New York Genome Center, New York, NY, USA.
    • Rashesh Sanghvi, MS. New York Genome Center, New York, NY, USA.
    • Elisa Venturini, MS/PharmD. New York Genome Center, New York, NY, USA.
    • Benjamin Hubert, PhD. New York Genome Center, New York, NY, USA.
    • Marcin Imielinski, MD, PhD. New York Genome Center, New York, NY, USA and Weill/Cornell Medicine, New York, NY, USA.
    • Nicolas Robine, PhD. New York Genome Center, New York, NY, USA.
  • Funding Source
    • P01 CA91955 Barrett's Esophagus: Predictors of Progression. National Institutes of Health, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA.
    • P30 CA015704 Cancer Center Support Grant. National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.
    • U54 CA217376 Arizona Cancer and Evolution Center (ACE). National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.
    • U2C CA233254 Breast Pre-Cancer Atlas Center. National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.
    • R01 CA140657 Modeling Neoplastic Progression in Barrett's Esophagus. National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.
    • BC 132057 Genomic Diversity and the Microenvironment as Drivers of Progressions in DCIS. CDMRP, Fort Detrick, MD, USA.
    • U24 CA15020 Genomic Data Network Visualization Genomic Data Center. National Institutes of Health, National Cancer Institute, Bethesda, MD, USA.
    • F31 CA 232465 Graduate Research Fellowship. National Institutes of Health, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA.
    • Burroughs Wellcome Fund Career Award for Medical Scientists. Burroughs Wellcome Fund, Research Triangle Park, NC, USA.
    • Doris Duke Clinical Foundation Clinical Scientist Career Development Award. Doris Duke Charitable Foundation, NY, NY, USA.